Vestibular migraine (VM) is one of the most common vestibular disorders, affecting 1.0% to 2.7% of the general population1, 7% of patients with definite migranous vertigo in dizziness clinics2, as well as 10.3% of VM patients in headache clinics3; 65% to 85% of VM patients are female1. Despite the relative prevalence of vestibular migraine, evidence-based medicine remains scarce. Two Cochrane reviews published in 2023 found that there is almost no evidence to support the use of medications for the acute treatment or preventive treatment of VM4,5.
Calcitonin gene-related peptide (CGRP) has been established as an excellent target for the treatment of migraine. Animal studies suggest a link between CGRP and vestibular disorders. A prospective observational cohort study found that monoclonal antibodies targeting CGRP receptors and ligands were very effective for vestibular migraine (VM), with 90% of participants experiencing at least a 50% reduction in vertigo attacks6. A small-scale prospective randomized controlled trial showed that a monoclonal antibody targeting a CGRP ligand significantly reduced the number of dizziness days per month in VM patients compared to placebo7. The efficacy of CGRP small molecule antagonists for the preventive and acute treatment of migraines has been widely recognized8,9. Therefore, we speculate that Rimegepant is effective for the preventive and acute treatment of vestibular migraine.
By focusing on a large sample RCT, our study can offer new evidence-based treatment options for patients with vestibular migraine. This is crucial, as many patients with vestibular migraine may not respond well to conventional migraine treatments. Our findings could guide clinicians in choosing more effective therapeutic strategies.
Specifically in acute treatment of vestibular migraine, triptans have failed to show superiority when compared to placebo in treatment vestibular migraine symptoms10. Prochlorperazine, a vestibular sedative, is widely used for acute treatment of vestibular migraine but is known to chronify symptoms11. Should rimegepant demonstrate superiority to placebo in this study, rimegepant could potentially become the first-line treatment for vestibular migraine across the world.

Start Date01 Apr 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

NCT06641466

/ RecruitingPhase 3

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE

The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.

Start Date13 Mar 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06728345

/ Not yet recruitingNot ApplicableIIT

The Real-world Study of Rimegepant for the Preventive Treatment in Female Migraine Patients

The goal of this observational study is to learn about the effects and safety of Rimegepant in women, especially young and middle-aged women, who take Rimegepant to treat their migraine in the real world. Participants already taking Rimegepant (75mg QOD) as their regular preventive treatment of migraine for 12 weeks will be evaluated as the followings :
1. To evaluate the change from baseline in the mean number of migraine days per month during weeks 1-12
2. To evaluate the number of participants that have least a 50% reduction from baseline in the mean number of migraine days per month during weeks 1-12

Start Date01 Dec 2024

Sponsor / Collaborator

The First Affiliated Hospital of Soochow University

100 Clinical Results associated with Rimegepant Sulfate

100 Translational Medicine associated with Rimegepant Sulfate

100 Patents (Medical) associated with Rimegepant Sulfate

253

Literatures (Medical) associated with Rimegepant Sulfate

01 Mar 2025·ANNALS OF INTERNAL MEDICINE

Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians

Review

Author: Shekelle, Paul G. ; Cooney, Thomas G. ; Yost, Jennifer ; Cross, J. Thomas ; Tice, Jeffrey A. ; Fitterman, Nick ; Obley, Adam J. ; Owens, Douglas K. ; Miller, Matthew C. ; Qaseem, Amir ; Shamliyan, Tatyana ; Etxeandia-Ikobaltzeta, Itziar ; Harrod, Curtis S. ; Linsky, Amy M. ; Hicks, Lauri A. ; Crandall, Carolyn J. ; Wilt, Timothy J. ; Maroto, Michael ; Lewis, Johanna

DESCRIPTION:

The American College of Physicians (ACP) developed this clinical guideline for clinicians caring for adults with episodic migraine headache (defined as 1 to 14 headache days per month) in outpatient settings.

METHODS:

ACP based these recommendations on systematic reviews of the comparative benefits and harms of pharmacologic treatments to prevent episodic migraine, patients' values and preferences, and economic evidence. ACP evaluated the comparative effectiveness of the following interventions: angiotensin-converting enzyme inhibitors (lisinopril), angiotensin II-receptor blockers (candesartan and telmisartan), antiseizure medications (valproate and topiramate), β-blockers (metoprolol and propranolol), calcitonin gene-related peptide (CGRP) antagonist-gepants (atogepant or rimegepant), CGRP monoclonal antibodies (eptinezumab, erenumab, fremanezumab, or galcanezumab), selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors (fluoxetine and venlafaxine), and a tricyclic antidepressant (amitriptyline). ACP used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to analyze the effects of pharmacologic treatment on the following outcomes: migraine frequency and duration, number of days medication was taken for acute treatment of migraine, frequency of migraine-related emergency department visits, migraine-related disability, quality of life and physical functioning, and discontinuations due to adverse events. In addition, adverse events were captured through U.S. Food and Drug Administration medication labels and eligible studies.

RECOMMENDATIONS:

In this guideline, ACP makes recommendations for clinicians to initiate monotherapy for episodic migraine prevention in nonpregnant adults in the outpatient setting as well as alternative approaches if initial treatments are not tolerated or result in an inadequate response. All 3 ACP recommendations have conditional strength and low-certainty evidence. Clinical considerations provide additional context for physicians and other clinicians.

01 Feb 2025·Pain and Therapy

Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study

Article

Author: Hutchinson, Susan ; Kudrow, David ; Fullerton, Terence ; Pixton, Glenn C. ; Pixton, Glenn C

INTRODUCTION:

Anxiety and depression are frequently associated with migraine, and antidepressant use can complicate treatment. These analyses assessed the safety and tolerability of rimegepant in participants with migraine and anxiety and/or depression, or using selective serotonin reuptake inhibitors (SSRIs) and/or other antidepressants.

METHODS:

Data were from a phase II/III safety study of rimegepant for the acute treatment of migraine. Participants with a history of 2-14 migraine attacks per month of moderate or severe pain intensity self-administered rimegepant 75 mg as needed up to once daily for up to 52 weeks. These post hoc subgroup analyses assessed safety according to self-reported history of anxiety (yes or no) or depression (yes or no), and current use of SSRIs (yes or no) or other antidepressants (yes or no).

RESULTS:

Of 1800 treated participants, 23.2% (n = 417) had a self-reported history of anxiety, 23.7% (n = 426) had a self-reported history of depression, and 11.2% (n = 202) reported both anxiety and depression. A total of 10.1% (n = 181) of participants were using an SSRI, 10.8% (n = 195) were using other antidepressants, and 1.8% (n = 32) were using both. Across the subgroups with anxiety, without anxiety, with depression, without depression, using SSRIs, not using SSRIs, using other antidepressants, and not using other antidepressants, respectively, similar proportions of participants reported adverse events (67.1%, 58.4%, 62.0%, 60.0%, 64.1%, 60.0%, 66.2%, 59.8%), serious adverse events (3.6%, 2.3%, 2.8%, 2.5%, 3.3%, 2.5%, 5.1%, 2.3%), and discontinuation of rimegepant due to adverse events (4.1%, 2.2%, 3.1%, 2.5%, 5.0%, 2.4%, 3.1%, 2.6%). Numerical improvements in a variety of participant-reported outcomes were also observed at weeks 12 and 52.

CONCLUSIONS:

Rimegepant showed favorable safety and tolerability in adults with migraine and a history of anxiety and/or depression and with SSRI and/or other antidepressant use.

TRIAL REGISTRATION:

Clinicaltrials.gov: NCT03266588.

01 Feb 2025·HEADACHE

Characterization of rimegepant drug–drug interactions using the cytochrome P450 probe drugs, itraconazole, rifampin, fluconazole, and midazolam

Article

Author: Croop, Robert ; Matschke, Kyle T. ; Bhardwaj, Rajinder ; Liu, Jing ; Morris, Beth ; Bertz, Richard

Abstract:

Objective:

Reported here are the results of four rimegepant phase I studies, in healthy participants, aimed at determining the in vivo potential of rimegepant (75 mg) for cytochrome P450 (CYP) 3A4‐related drug–drug interactions (DDIs).

Background:

Rimegepant orally disintegrating tablet (Pfizer Inc., New York, NY, USA) is a calcitonin gene‐related peptide receptor antagonist approved for acute treatment of migraine and preventive treatment of episodic migraine. People with migraine commonly use multiple drug treatments, with the potential for DDIs.

Methods:

Each study was an open‐label, single‐arm, single‐sequence, crossover study. Rimegepant was tested as a victim drug by separate co‐administration of itraconazole (a strong CYP3A4 inhibitor and P‐glycoprotein inhibitor) in Study 1, rifampin (a strong CYP3A4 inducer and moderate CYP2C9 inducer) in Study 2, and fluconazole (a strong CYP2C9 inhibitor and moderate CYP3A4 inhibitor) in Study 3, and as a perpetrator drug by co‐administration with midazolam (a CYP3A4 substrate) in Study 4.

Results:

Mean values of single‐dose rimegepant maximum concentration (Cmax) and area under the curve from time 0 to infinity (AUC0–inf) increased with itraconazole co‐administration (n = 22) by 1.42‐fold (90% confidence interval [CI] 1.25–1.61) and by 4.14‐fold (90% CI 3.87–4.44), respectively, and decreased with rifampin co‐administration (n = 21) to 36% (90% CI 31.2–41.4%) and to 19% (90% CI 16.3–21.4%), respectively. Co‐administration with fluconazole (n = 23) increased rimegepant mean AUC0–inf by 1.80‐fold (90% CI 1.68–1.93), with no impact on Cmax (1.04‐fold; 90% CI 0.94–1.15). Co‐administration of rimegepant single dose (300 mg; n = 14) or multiple doses (150 mg/day; n = 14) increased the mean Cmax of midazolam by 1.38‐fold (90% CI 1.13–1.67) and 1.53‐fold (90% CI 1.32–1.78), respectively, and the AUC0–inf of midazolam by 1.86‐fold (90% CI 1.58–2.19) and 1.91‐fold (90% CI 1.63–2.25), respectively.

Conclusions:

Based on the magnitude of DDIs, these studies indicate the following: co‐administration of rimegepant with a strong CYP3A4 inhibitor should be avoided; during co‐administration with a moderate CYP3A4 inhibitor, another dose of rimegepant within 48 h should be avoided; co‐administration of rimegepant with a strong or moderate CYP3A4 inducer should be avoided; CYP2C9 does not play a meaningful role in rimegepant metabolism; and there is no clinically meaningful CYP3A4 inhibition by rimegepant.

News (Medical) associated with Rimegepant Sulfate

06 Feb 2025

·www.echemi.com

Pfizer Reports 2024 Earnings with $63.6 Billion Revenue and Concerns Over Innovation

On February 4, Pfizer announced its financial results for the fourth quarter and the entire year of 2024, revealing a total revenue of $63.6 billion, a 7% increase year-on-year. The fourth quarter alone saw revenues of $17.8 billion, reflecting a substantial 22% growth compared to the same period last year. However, the net profit for the year was $8.031 billion, with only $410 million generated in the fourth quarter, raising concerns among investors. Pfizer operates through three main business segments: Generic Medicines, Specialty Medicines, and Oncology. The Generic Medicines division reported annual revenues of $30.135 billion, a 2% decline from the previous year. In contrast, the Specialty Medicines segment achieved $16.652 billion in revenue, marking an 11% increase, while the Oncology division saw a 25% rise in revenue, totaling $15.612 billion. In the Generic Medicines segment, sales of the COVID-19 vaccine reached $5.353 billion, down 52% year-on-year. Despite this significant drop, there is no indication that the vaccine has fallen out of favor. Sales of apixaban totaled $7.366 billion, up 9%, although this product is nearing the end of its lifecycle. The pneumonia vaccine family generated $6.411 billion, a slight 1% decline. Notably, sales of Rimegepant, an oral CGRP inhibitor, surged to $1.263 billion, a 36% increase from 2022. The RSV bivalent vaccine Abrysvo brought in $755 million, down approximately $150 million from the previous year. Other pipeline products primarily consist of Pfizer's mature offerings, which generally experienced declines. In the Specialty Medicines sector, the drug Vyndaqel for transthyretin amyloidosis proved to be a significant revenue generator, contributing $5.411 billion in sales, a remarkable 64% increase. However, sales of tofacitinib fell 31% to $1.168 billion due to patent cliffs affecting the immediate-release formulation. The older drug ilaprazole saw sales of $690 million, down 17% year-on-year. Surprisingly, the antibiotic sufentanil still managed to generate $637 million in sales, despite a 4% decline, with a significant portion likely coming from China. The injectable ceftazidime-avibactam (Sivextro) achieved $586 million in sales, a 16% decline, marking it as the first cephalosporin antibiotic to surpass $500 million in sales since 2010. In the Oncology division, palbociclib generated $4.367 billion, down 8% year-on-year. Enzalutamide saw revenues of $2.039 billion, a 23% increase. The new drug padcev (enfortumab vedotin) performed exceptionally well, achieving $1.588 billion in sales during its first full fiscal year. Adcetris (brentuximab vedotin) also showed strong performance, with sales soaring to $1.089 billion. Axitinib generated $978 million, down 6%, while bosutinib remained stable at $645 million. Despite maintaining its position as the world's largest pharmaceutical company, Pfizer faces significant challenges regarding innovation and pipeline development. As of December 2024, the company's market capitalization stood at $150 billion, significantly lower than competitors such as Eli Lilly ($750 billion), Johnson & Johnson ($350 billion), AbbVie ($320 billion), Novo Nordisk ($300 billion), Merck ($250 billion), Roche ($220 billion), Novartis ($210 billion), and AstraZeneca ($200 billion). The pressure to innovate and expand its product pipeline remains a critical concern for Pfizer moving forward.

VaccineFinancial StatementDrug ApprovalClinical ResultBiosimilar

27 Jan 2025

·www.fiercepharma.com

Pfizer shells out nearly $60M to resolve Nurtec kickback claims inherited in Biohaven buyout

A recent settlement resolves allegations that Biohaven induced doctors to write Nurtec prescriptions by paying “improper remuneration," including through speaker payouts and meals at “high end restaurants." Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments intended to boost prescriptions. Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays.Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing more than $59.7 million to resolve the kickback allegations against its subsidiary, the DOJ said Friday.The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown jewel in Pfizer’s Biohaven buyout, delivered $928 million in 2023 sales. Pfizer reports its fourth-quarter 2024 financial results next week, and the drug is expected to cross the $1 billion mark for the first time.The settlement resolves allegations—brought forward in a 2021 whistleblower lawsuit—that Biohaven induced doctors to write Nurtec prescriptions by paying “improper remuneration," including through speaker payouts and meals at “high end restaurants," according to a DOJ press release on Monday.Prescribers who attended multiple educational programs on the same topic “received no educational benefit from attending repeat programs,” the DOJ said in its release, while other Biohaven speaker programs were attended by people with no educational need to be there, such as speakers’ spouses, family members or friends.Pfizer’s buyout of Biohaven officially closed Oct. 3, 2022.“The settlement relates to alleged conduct at Biohaven before Pfizer’s acquisition of the company in October 2022 and does not include any admission of liability or wrongdoing,” a Pfizer spokesperson said in an emailed statement.Pfizer is “pleased to put this legacy matter behind us, so that we can continue to focus on the needs of patients," the company's spokesperson said. The allegations against Biohaven first came to light when an ex-staffer filed a whistleblower lawsuit against her former company in the summer of 2021. As part of the deal with the DOJ, the former staffer is in line to receive roughly $8.4 million as her share of the federal settlement, the government explained.While Nurtec was already on a rapid ascent by the time of Biohaven’s acquisition, Pfizer has helped raise the migraine med’s profile even more thanks in part to an ad campaign with award-winning musician and actor Lady Gaga.Biohaven isn't alone in facing allegations over kickbacks in recent years.Last fall, Teva Pharmaceuticals USA and Teva Neuroscience forked over a combined $450 million in a DOJ settlement to resolve claims that they leveraged assistance foundations to fund patients’ copays for the multiple sclerosis blockbuster Copaxone from 2006 through 2017. Prior to that, Biogen in 2022 finalized an agreement to pay $900 million to resolve a lawsuit alleging it paid kickbacks to doctors over a five-year span to boost sales of its own multiple sclerosis drugs. Novartis has also found itself in the DOJ’s sights, paying more than $642 million in 2020 to resolve claims that it offered kickbacks to doctors and illegal copayment support to Medicare to improve pharmaceutical sales.

AcquisitionPatent InfringementDrug Approval

30 Dec 2024

·www.prnewswire.com

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx's VYVDURA (efgartigimod alfa and hyaluronidase-qvfc), which is co-formulated with Halozyme's ENHANZE® drug delivery technology, was granted regulatory approval by Japan's Ministry of Health, Labour and Welfare (MHLW) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVDURA was approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP. "We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized myasthenia gravis and CIDP patients," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We look forward to VYVDURA being a new treatment option for an even broader number of patients in Japan." The MHLW approval is based on the ADHERE Study, the largest clinical trial to date studying CIDP. In the ADHERE study, 69% (221/322) of patients treated with VYVDURA, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. Ninety-nine percent of trial participants elected to participate in the ADHERE+ open-label extension. The safety results were generally consistent with the known safety profile of VYVDURA in previous clinical studies and real-world use. VYVDURA was also approved by the MHLW for manufacturing and marketing in January 2024 and launched in April 2024 for the treatment of generalized myasthenia gravis (gMG). In March 2024, VYVDURA was designated as an Orphan Drug for the treatment of CIDP by the MHLW. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched more than 800,000 patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including offering flexibility to receive treatment in more convenient locations and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram Bui VP, Investor Relations and Corporate Communications 609-359-3016 [email protected] Samantha Gaspar Teneo 212-886-9356 [email protected] SOURCE Halozyme Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalOrphan DrugClinical Result

100 Deals associated with Rimegepant Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Rimegepant Sulfate	N02C	DB12457

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute migraine	South Korea	Pfizer Pharmaceuticals Korea Ltd.	24 Mar 2025
Migraine Disorders	United States	Pfizer Inc.	27 Feb 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine Without Aura	Phase 3	United States	Pfizer Inc.	13 Mar 2025
Temporomandibular Joint Disorders	Phase 3	United States	Pfizer Inc.	05 May 2022
Chronic rhinosinusitis with nasal polyps	Phase 3	United States	Pfizer Inc.	17 Feb 2022
Nasal Polyps	Phase 3	United States	Pfizer Inc.	17 Feb 2022
Migraine With Aura	Phase 3	United States	Pfizer Inc.	28 Apr 2021
Migraine With Aura	Phase 3	Poland	Pfizer Inc.	28 Apr 2021
Migraine With Aura	Phase 3	Spain	Pfizer Inc.	28 Apr 2021
Abdominal Pain	Phase 2	United States	Pfizer Inc.	06 Jun 2024
Irritable Bowel Syndrome	Phase 2	United States	Pfizer Inc.	06 Jun 2024
Plaque psoriasis	Phase 2	United States	Pfizer Inc.	19 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05371652 (CTgov)	Phase 3	Acute migraine	241	Rimegepant	bzyvcvpvum = umaigmxghw vyaownvvxo (oxmfdqdqut, tjpxvwlzpz - ctejdgjhsg) View more	-	25 Mar 2025
NCT05399459 (CTgov)	Phase 3	Migraine Disorders	897	Rimegepant 25 MG (Rimegepant 25 mg)	gsfkbkyeeu = mckijykags ybzuseunzh (nbsodfomed, uwwxjmwekp - tbgljlytqe) View more	-	10 Feb 2025
				Rimegepant 75 MG (Rimegepant 75 mg)	gsfkbkyeeu = kpzemrcvas ybzuseunzh (nbsodfomed, mzkqdclsgo - eaqpqddhrs) View more
NCT03266588 (phase II/III safety study of rimegepant, Pubmed \| Pain Ther)	Phase 2/3	anxiety \| depression \| SSRIs ... View more	1,800	Rimegepant 75 mg	zrfuyhadqa(aupcmlzskb) = nuizjunndd kvamxjagny (jgjyzxhpbv ) View more	Positive	09 Nov 2024
				Placebo	zrfuyhadqa(aupcmlzskb) = iwtttyanwf kvamxjagny (jgjyzxhpbv ) View more
NCT03266588 (Pubmed) Manual	Phase 2/3	Migraine Disorders	1,800	Rimegepant 75 mg	ktjgqxdxbx(erabwnvtqs) = xguirobocb ryoandlhfs (wpbgagjmkn ) View more	Positive	10 Jul 2024
				Rimegepant (CV risk 1)	ktjgqxdxbx(erabwnvtqs) = dtjqasiuij ryoandlhfs (wpbgagjmkn ) View more
NCT03235479 (Pubmed) Manual	Phase 3	Migraine Disorders	1,162	Rimegepant 75 mg oral tablet	dikomdmkkb(ejrjccqyxx) = bragjutumg fjnkbnllez (ydtvqhcyxw ) View more	Positive	01 Jul 2024
				Placebo	dikomdmkkb(ejrjccqyxx) = tlfrzftwkj fjnkbnllez (ydtvqhcyxw ) View more
NCT03941834 (BHV3000-202, CTgov)	Phase 2	Trigeminal Neuralgia	65	Rimegepant (DBT Phase: Pooled Rimegepant)	bqscrgxpof(mhrivddrdf) = gbaonpvoyd agujulfgdr (ayekojkarz, ccwjwzpfon - yhlpgcgmmx) View more	-	10 Jun 2024
				placebo+rimegepant (DBT Phase: Pooled Placebo)	bqscrgxpof(mhrivddrdf) = woyziurrzw agujulfgdr (ayekojkarz, cmlvwsoxzs - thzhfcugwb) View more
NCT05262517 (CTgov)	Phase 3	Temporomandibular Joint Disorders	126	Rimegepant (BHV3000 (Rimegepant (BHV3000))	afhgusghew(uvkgaspcwj) = dkvekhxvhq fhkgnhgwex (raiglffmvh, rmsmwnhurh - wcaijhpsrd) View more	-	16 May 2024
				placebo+rimegepant (Placebo)	afhgusghew(uvkgaspcwj) = mdislklhsk fhkgnhgwex (raiglffmvh, nkotxbnohn - gnpmyvlovv) View more
NCT04574362 (Pubmed) Manual	Phase 3	Acute migraine	1,075	Rimegepant ODT 75 mg	bwljjgwkwd(rzbzuhuggp) = fumjtkhwxr bzvrkhopri (ffkwhteobo ) View more	Positive	16 Apr 2024
				Placebo	bwljjgwkwd(rzbzuhuggp) = txannjyngp bzvrkhopri (ffkwhteobo ) View more
P7-12.010 (AAN2024)	Not Applicable	Migraine Disorders CGRP	10	Rimegepant	ecwaahdsqy(sxlpehztzp) = other had dyspepsia cqkihvbpnn (xqzkwarfxl ) View more	Positive	09 Apr 2024
AAN2024	Not Applicable	Migraine Disorders	-	Rimegepant	oszxwvzijr(notflizcqa) = ptankvpabf skswbmetsf (clphqyejum, 56.0%–60.2%) View more	-	09 Apr 2024
				Zavegepant	oszxwvzijr(notflizcqa) = yswaatnoph skswbmetsf (clphqyejum, 56.4%–62.5%) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis